AC
PRTA icon

Ascend Capital’s Prothena Corp PRTA Stock Holding History

Ascend Capital’s Portfolio PRTA Stock Details PRTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-116,059
Closed -$7.52M – 240
2017
Q3 		$7.52M Buy
116,059
+9,659
+9% +$592K 0.28% 94
2017
Q2 		$5.76M Buy
+106,400
New +$5.67M 0.27% 100

Other funds holding PRTA

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ascend Capital's PRTA Position: Q4 2017 in Review

Ascend Capital sold out of Prothena Corp (PRTA) in Q4 2017, closing a stake of 116,059 shares — an estimated $7.52M sold.

Ascend Capital first reported a position in PRTA in Q2 2017 and held it in 2 quarters. The position peaked at $7.52M in Q3 2017. 155 funds tracked by Wall St. Rank hold PRTA as of Q4 2017.

  • Ascend Capital reported no remaining Prothena Corp position as of Q4 2017 after selling out during the quarter.
  • Ascend Capital sold 116,059 Prothena Corp shares in Q4 2017, an estimated $7.52M.
  • Ascend Capital first reported a position in Prothena Corp in Q2 2017 and held it in 2 quarters.
  • Ascend Capital's Prothena Corp position peaked at $7.52M in Q3 2017.
  • 155 funds tracked by Wall St. Rank held Prothena Corp as of Q4 2017.

Based on Ascend Capital's 13F filing for Q4 2017, filed 13 Feb 2018.